Previous 10 |
home / stock / iphyf / iphyf news
Innate Pharma ( OTCPK:IPHYF ) has licensed the US and EU commercial rights of AstraZeneca’s (NYSE: AZN ) FDA approved medicine for Hairy Cell Leukemia (HCL), Lumoxiti, marking the first step of its strategy to become a fully integrated company. More news on: Innate Pharm...
Innate Pharma S.A. ( OTCPK:IPHYF ): FY GAAP EPS of €0.05. More news on: Innate Pharma S.A., Earnings news and commentary, Read more ...
Introduction NK (natural killer) cells can attack cancer cells even when T cells cannot. However, like T cells, NK cells have inhibitory (checkpoint) receptors that tumor cells exploit to silence them. Innate’s monalizumab blocks the NKG2A receptor, and represents a novel and much nee...
Reuters reports that AstraZeneca (NYSE: AZN ) will acquire a 9.8% stake in French outfit Innate Pharma ( OTCPK:IPHYF ) via the purchase of ~6.26M newly issued shares at 10 euros per share. More news on: AstraZeneca Group plc, Innate Pharma, Healthcare stocks news, Merger & acquisitio...
Innate Pharma SA (IPHYF) H1 2018 Results Conference Call September 14, 2018 08:00 ET Executives Mondher Mahjoubi - CEO Laure-Helene Mercier - CFO Pierre Dodion - CMO Analysts Jonathan Chang - Leerink Partners Presentation Operator Good afternoon ladies and gentlem...
Innate Pharma ( OTCPK:IPHYF ): FY EPS of -€0.89 More news on: Innate Pharma, Innate Pharma ADR, Earnings news and commentary, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Pari...
SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS SAR443579/IPH6101 continues ...
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety profile consistent with prior studies. Innate will host a virtual KOL...